Identification of ANT2 as a Druggable Target for Endocrine-Resistant ERα-Positive Breast Cancer
International Journal of Molecular Sciences · 21.04.2026 · 27 (8) · 3704
DOI: 10.3390/ijms27083704 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 21.04.2026. Verfasst von Erika Iguchi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566,…. Hauptthemen laut MEDLINE: Breast Neoplasms, Estrogen Receptor alpha, Drug Resistance, Neoplasm, Adenine Nucleotide Translocator 2. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kyoto Preventive Medical Center Cancer Grant in Aid, JSPS KAKENHI Scientific Research (C), JSPS KAKENHI Challenging Research (Exploratory).
Abstract (Originalsprache)
Endocrine therapy is the mainstay for estrogen receptor (ER) α-positive breast cancer (BC), yet many patients display acquired resistance. We then screened natural compounds using human ERα-positive BC cells and identified perillyl alcohol (POH), a monoterpene from perilla, that reduces ERα protein levels. Chemoproteome analysis using POH-immobilized nanomagnetic beads revealed adenine nucleotide translocase 2 (ANT2), a mitochondrial inner membrane protein, as a direct target of POH. Molecular dynamics (MD) simulations predicted POH binding to the central pore of ANT2, which functions in ATP transport. ANT2 depletion reduced ERα levels, and public datasets indicate that high ANT2 expression correlates with poor prognosis in ERα-positive BC. POH also inhibited the growth of Tamoxifen- and Fulvestrant-resistant BC cells. RNA sequencing showed that fatty acid elongation-related genes were upregulated in Fulvestrant-resistant cells but downregulated by ANT2 depletion. Both ANT2 depletion and POH treatment led to the accumulation of intracellular lipid droplets in Fulvestrant-resistant cells, consistent with impaired fatty acid elongation. Finally, in silico screening using MD simulations identified venetoclax and nystatin as potential ANT2 pore binders. Both compounds reduced ERα levels in ERα-positive BC cells and increased lipid droplet formation in Fulvestrant-resistant cells. These findings highlight ANT2 as a druggable target against endocrine-resistant BC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.
- Department of Molecular-Targeting Prevention, Kyoto Prefectural University of Medicine, 465 Kajii-cho Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.
- Artificial Intelligence Research Center, National Institute of Advanced Industrial Science and Technology (AIST), 2-4-7 Aomi, Koto-ku, Tokyo 135-0064, Japan.
- Department of Clinical Oncology, Kansai Medical University Hospital, 2-3-1, Shinmachi, Hirakata 573-1191, Japan.
ORCID-Profile: Erika Iguchi, Motoki Watanabe, Shogen Boku, Midori Morita, Michihiro Mutoh, Tomoshi Kameda
Förderung
- Kyoto Preventive Medical Center Cancer Grant in Aid
- JSPS KAKENHI Scientific Research (C)
- JSPS KAKENHI Challenging Research (Exploratory)
Zitieren
APA
Iguchi, E., Watanabe, M., Kobayashi, K., Boku, S., Nishio, W., Kato, C., Morita, M., Sakaguchi, K., Mutoh, M., Kameda, T., & Naoi, Y. (2026). Identification of ANT2 as a Druggable Target for Endocrine-Resistant ERα-Positive Breast Cancer. International Journal of Molecular Sciences, 27(8), 3704. https://doi.org/10.3390/ijms27083704
Vancouver
Iguchi E, Watanabe M, Kobayashi K, Boku S, Nishio W, Kato C, et al. Identification of ANT2 as a Druggable Target for Endocrine-Resistant ERα-Positive Breast Cancer. International Journal of Molecular Sciences. 2026;27(8):3704. doi:10.3390/ijms27083704
BibTeX
@article{Iguchi2026,
author = {Iguchi, Erika and Watanabe, Motoki and Kobayashi, Kaito and Boku, Shogen and Nishio, Wataru and Kato, Chikage and Morita, Midori and Sakaguchi, Koichi and Mutoh, Michihiro and Kameda, Tomoshi and Naoi, Yasuto},
title = {Identification of ANT2 as a Druggable Target for Endocrine-Resistant ERα-Positive Breast Cancer},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {8},
pages = {3704},
doi = {10.3390/ijms27083704}
}
EUVIMED